Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Metamfetaminisomerfarmakologi hos mennesker

30. oktober 2026 oppdatert av: University of Wisconsin, Madison

The Low-Down on Metamfetamin-isomerer: Prevalens og farmakologi hos mennesker

This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.

Studieoversikt

Detaljert beskrivelse

Double-blind crossover study design. Healthy volunteers will attend three study drug administration visits, at least 7 days apart, in which methamphetamine isomer pharmacology will be assessed following intravenous administration of (1) S-(+)-methamphetamine, (2) R(-)-methamphetamine, or (3) a (1:1) racemic mixture of R-(-)- and S-(+)-methamphetamine. The order of these interventions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick, oral fluid collections, and pooled urine specimens.

Primary Objective

  • Characterize the pharmacokinetics of acute S-(+)-methamphetamine administration.
  • Characterize the pharmacokinetics of acute R-(-)-methamphetamine administration.
  • Characterize the pharmacokinetics of acute racemic (1:1) R-(-)- and S-(+)-methamphetamine administration.

Secondary Objectives

  • Assess for evidence of stereo-selective metabolic pathways.
  • Assess for evidence of subjective, cognitive, or physiological effects from acute R-(-)-methamphetamine administration.
  • Assess for evidence of more than additive effects when administering racemic methamphetamine.

Correlative Objectives

  • Compare biological methamphetamine and metabolite concentrations in surveyed biological matrices (i.e., plasma, whole blood, oral fluid, dried capillary blood spots, and urine) over time.
  • Compare cognitive and subjective effects of acute S-(+)-methamphetamine, R-(-)-methamphetamine, and racemic methamphetamine administration.

Studietype

Intervensjonell

Registrering (Antatt)

17

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53705
        • University of Wisconsin

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 64 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Good mental health as determined by self-reported responses to the Psychopathology Screener
  • Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener
  • English-speaking (able to provide consent and complete questionnaires)
  • Written Informed Consent

Exclusion Criteria:

  • Any serious prior adverse response to sympathomimetic agents or amphetamine analogs
  • History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener
  • Pregnancy or lactation (pregnancy test, if needed)
  • Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)
  • Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: S-Meth, R-Meth, Racemic Isomer

First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine

15 mg

Andre navn:
  • S-Meth

15 mg

Andre navn:
  • R-Meth

15 mg R-Meth + 15 mg S-Meth

Eksperimentell: R-Meth, Racemic Isomer, S-Meth

First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth

15 mg

Andre navn:
  • S-Meth

15 mg

Andre navn:
  • R-Meth

15 mg R-Meth + 15 mg S-Meth

Eksperimentell: Racemic Isomer, S-Meth, R-Meth

First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth

15 mg

Andre navn:
  • S-Meth

15 mg

Andre navn:
  • R-Meth

15 mg R-Meth + 15 mg S-Meth

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Peak concentration (Cmax)
Tidsramme: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study.

pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
Area under the concentration versus time curve (AUC)
Tidsramme: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study.

pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive Effects: Divided Attention Task (DAT)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

The DAT requires participants track a moving stimulus on a computer screen while simultaneously monitoring numbers located in the corners of the screen. Participants must respond to target numbers as they appear, and the task quantifies mean distance of the mouse cursor from the center of the target stimulus.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Cognitive Effects: Digital Symbol Substitution Task (DSST)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

The DSST asks participants to recreate patterns of various shapes presented on a computer screen using the keyboard. The total number of correct patterns are recorded within 90 seconds.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Cognitive Effects: Paced Serial Addition Task (PASAT)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

The PASAT has participants view a string of single-digit numbers and calculate the sum of the two most recently presented numbers. The total number of correct trials out of 90 will be recorded.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Subjective Effects: Drug Effect Questionnaire (DEQ)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

Subjective current general effects will be measured by asking the participant to rate if they feel the drug effect, if they like/dislike the drug effect, if they feel high, and if they would like more of the drug. Effects will be measured on a scale from "not at all" anchored at 0 to "extremely" at 100.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Subjective Effects: Number of Participants Who Answer 'True' for Amphetamine-specific questions
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

Participants will be asked 11 amphetamine-specific questions including feelings of pleasantness, excitability, memory, emptiness, body tingling, weird feeling, patience, and mental sharpness. Results are measured as either "true" (experiencing the specific state) or "false" (not experiencing the specific state). Number of participants who answered 'True' is reported here

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Heather K Barkholtz, PhD, University of Wisconsin, Madison
  • Hovedetterforsker: David Leinweber, MD, University of Wisconsin, Madison

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. januar 2029

Studiet fullført (Antatt)

1. januar 2029

Datoer for studieregistrering

Først innsendt

9. desember 2024

Først innsendt som oppfylte QC-kriteriene

18. desember 2024

Først lagt ut (Faktiske)

24. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. oktober 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2024-1164
  • A523000 (Annen identifikator: UW Madison)
  • Protocol Version 2/12/25 (Annen identifikator: UW Madison)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere